A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

This is a first in human, Phase 1/2 open-label multi-center, dose escalation and expansion study to evaluate the safety, tolerability, PK, PD and efficacy of RNK05047 when administered an intravenous (IV) infusion to subjects with advanced solid tumors, including diffuse large B-cell lymphoma (DLBCL). This is a 2-part study (dose escalation, cohort expansion) with sequential enrollment.

Trial Details

NCT ID
NCT05487170
Phase
PHASE1 / PHASE2
Sponsor
Ranok Therapeutics (Hangzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • RNK05047
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • New York, New York, United States|40.71427,-74.00597
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Pathologically documented locally advanced or metastatic solid tumor
  • Refractory or intolerant to all available standard-of-care therapies for advanced disease
  • Measurable disease
  • Archived tumor tissue collected

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →